NPCE

Analyst Note: NeuroPace, Inc. (NPCE)

Date: 2026-06-13 Sector: Healthcare | Industry: Medical Devices

1. Structural Readiness

• Conservative Entry: $18.35
• Current Price: $15.63
• Extension: -14.8% vs. conservative entry.
• Breakout Level: $18.35 (Conservative) / $16.54 (Aggressive/Structural Support).
• ATR Context: ATR at breakout was 4.8% (High structural quality). Current ATR is 5.1% (High volatility).

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Secular Exposure: No named secular thesis is attached to this specific setup at this date.
• Judgment Criteria: The investment case must be judged strictly on the quality of the technical setup (which is currently failed) and the underlying business fundamentals. There is no macro or secular tailwind explicitly driving this specific trade setup; the conviction must derive from the company's operational execution and regulatory progress, not a broad market theme.

3. Business Overview

NeuroPace, Inc. operates in the medical device sector, specializing in the RNS System, a brain-responsive neuromodulation device for the treatment of drug-resistant focal epilepsy. The company generates revenue through the sale of devices for initial surgical implantations and subsequent replacement procedures.

Key Operational Data (as of 2026-06-13):

• Revenue Performance: In the quarter ended March 31, 2026, the company reported total revenue of $22.1 million. Excluding DIXI Medical, revenue was $22.0 million, representing 8% year-over-year growth. RNS System revenue specifically was $21.7 million.
• Growth Drivers: Management states that the majority of growth is driven by Level 4 comprehensive epilepsy centers (CECs).
• Guidance: On May 12, 2026, management raised full-year 2026 revenue guidance to a range of $99 million to $101 million, up from the previous range of $98 million to $100 million. This guidance reflects 21% to 23% underlying RNS growth from the existing adult focal indication.
• Regulatory Pipeline:
• NAUTILUS PMA-Supplement: A mid-cycle review meeting was completed in the quarter. Management expects a mid-year determination (mid-2026) for the expansion of the indication to include drug-resistant idiopathic generalized epilepsy.
• ECoG Assistant: Management expects approval for this product in the second quarter of 2026.
• Clinical Data:
• Focal Epilepsy: Post-approval study data shows efficacy improves over time, with a 62.5% median seizure reduction at 6 months and 82.0% at 36 months.
• Generalized Epilepsy: 18-month data presented in April 2026 demonstrated a 77% median reduction in generalized tonic-clonic seizures in a refractory population.
• Financial Position: As of March 31, 2026, the company held $54.0 million in cash, cash equivalents, and short-term investments against an accumulated deficit of $559.1 million and $59.0 million in outstanding debt.

4. Archetype and Conviction Stack

• Archetype: Growth Leader.
• Rationale: The company demonstrates consistent revenue growth (8% YoY, 21-23% underlying RNS growth) and is actively expanding its addressable market through regulatory approvals (Generalized Epilepsy). The business model relies on high-value implants and recurring replacement revenue, supported by a growing installed base of over 8,000 patients.
• Valuation & Financial Spine:
• Forward consensus EPS for FY1 is projected at -0.61481 and FY2 at -0.33411. The company remains in a pre-profitability growth phase, typical for specialized med-tech firms with significant R&D and regulatory costs.
• Conviction Stack:
• Thesis Strength: Moderate. The business fundamentals are strong (guidance raise, clear regulatory path), but the setup is currently broken.
• Evidence Quality: High. Recent earnings transcripts and SEC filings provide specific, quantified data on revenue, guidance, and clinical outcomes.
• Structural Quality: The ATR at breakout (4.8%) indicated a high-quality structure historically, but the current price action has invalidated this.
• Rerating Potential: High, contingent on the successful mid-year regulatory determination for the NAUTILUS PMA-Supplement and the ECoG Assistant approval.

5. Invalidating and Strengthening Factors

• Invalidating Factors:
• Fundamental: Failure to receive the anticipated mid-year FDA determination for the generalized epilepsy indication or rejection of the ECoG Assistant application would materially impact the growth thesis.
• Strengthening Factors:
• Technical: A decisive breakout above the conservative entry ($18.35) would re-establish the "Confirmed" state.
• Fundamental: Confirmation of the mid-year FDA approval for the NAUTILUS PMA-Supplement and the ECoG Assistant approval would validate the guidance raise and expand the total addressable market.
• Evidence Gaps:
• Cash Runway: While $54.0 million is available, the accumulated deficit of $559.1 million and the need for continued R&D/regulatory spending create a gap in long-term capital certainty without further equity/debt raises.
• Commercial Execution: The reliance on Level 4 CECs is a strength, but the evidence regarding the speed of adoption in community settings (outside Level 4) remains a variable to watch.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key risks: Potential for a sharp rebound if FDA approval is announced immediately; High volatility could lead to rapid mean reversion if the setup re-forms; Regulatory approval could be delayed beyond mid-year expectations. Sizing hint: Position size should be zero or reduced to zero; do not attempt to catch a falling knife on an invalidated structure. Expected path: Management expects mid-year FDA determination for NAUTILUS and ECoG Assistant approval in Q2 2026; structural recovery requires price to reclaim and hold above $18.35. Expected horizon: 3 to 6 months for regulatory clarity and potential structural reformation. Failure mode to watch: A sustained close below $15.00 would indicate a deeper structural breakdown and potential liquidity issues.